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This was a prospective, observational study designed to test a nutrition
algorithm for 1) clinical feasibility; 2) logical progression; 3) ability to collect
data; and 4) effectiveness in improving outcomes. Patients included in this
study were enrolled by renal dietitians (RD) working in HD units based in ﬁve
different countries. To select study subjects, RD were asked to screen and
consent patients in their facilities until 4 patients were identiﬁed as at
nutrition risk per the algorithm’s screening tool. All data were collected via
the algorithm including screening, assessment, nutrition related diagnosis,
etiology of the nutrition diagnosis, nutrition related barriers, nutrition focused
interventions, and outcome parameters. Statistics were performed using SPSS
vs 20.0 and signiﬁcance set at po0.05. One hundred patients, enrolled by 29
RD, were included in this analysis. The screening parameters that triggered an
‘‘at risk ﬂag’’ for more than 50% of the patients were: PTH, serum cholesterol
and unintentional weight loss. Of the patients with an albumin of o3.8 mg/dl
(37% of sample), 73% were given a nutritional diagnosis of insufﬁcient protein
intake. Overall, patients with insufﬁcient intake had signiﬁcantly lower serum
albumin concentrations at baseline than those who did not have this
(3.770.4 vs. 4.070.4, po0.05). Patients with a diagnosis of ‘‘high
phosphorus’’ had decreases in serum PTH (349.57184.5 to 201.77113.6,
p¼0.06) and phosphorus (from 6.571.0–5.371.9 mg/dl, p¼0.04) at the
three month data collection. This study is the ﬁrst of its kind to show that a
web-based, HD speciﬁc, nutrition algorithm is feasible and effective.
http://dx.doi.org/10.1016/j.krcp.2012.04.554
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Whilst L-carnitine (LC) supplementation is recommended for the
treatment of EPO-resistant anemia, the extent of effectiveness has been
shown to vary considerably. Previous work by Reuter et al (2008)
demonstrated a signiﬁcant association between EPO-resistance and
carnitine pool composition; based on these ﬁndings, it is hypothesized that
patients who have a high EPO resistance index (ERI) are more likely to
respond to LC supplementation. Preliminary assessment of this hypothesis
was conducted as retrospective analysis, using prospectively-deﬁned
criteria, of data from 2 randomized, double-blind, placebo-controlled trials.
HD patients were administered LC (20 mg/kg/wk/dialysis i.v.) or placebo
for 24 weeks, with EPO dose and hemoglobin data assessed at Weeks 0, 12
& 24. Patients were classiﬁed as High (40.02 mg/kg/wk/gHb) or Low ERI
based on baseline data. Treatment effectiveness was analyzed using
%baseline ERI for all patients (Low ERI & High ERI) and for High ERI patients
only. 77 patients (38 LC/39 placebo) were included in the analysis, of which
22 (14 LC/8 placebo) were classiﬁed as High ERI. Analysis of all patient data
indicated no signiﬁcant differences between Week 0, 12 & 24 %baseline ERI
for neither the LC nor placebo groups, whereas analysis of High ERI patient
data indicated a signiﬁcant reduction in %baseline ERI at Week 12 & 24
compared to Week 0 (p¼0.004) for the LC treatment group, with no
signiﬁcant placebo treatment effect. Similarly, analysis of %baseline ERI
area-under-the-curve from 0–241weeks indicated no signiﬁcant treatment
effects when all patients were included in the analysis, whereas for High
ERI patients, signiﬁcantly lower values were demonstrated for LC vs
placebo (p¼0.016). These ﬁndings suggest that High ERI patients may
receive the most beneﬁt from LC supplementation. It is proposed that LC
treatment results in an improvement in CPT activity via normalization of
the LC/acylcarnitine ratio, thereby resulting in stabilization of the RBC
membrane and improvement in anemia. A randomized, double-blind,
placebo-controlled study is being conducted to investigate this further.
http://dx.doi.org/10.1016/j.krcp.2012.04.555
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Dietary intake of selenium (Se) plays an important role as an antioxidant and
anti-inﬂammatory agent due to its antioxidant properties and the richest
known food source of Se is the Brazilian nut, found in the Amazon region,
Brazil. The aim of this study was to evaluate the effect of the Brazilian nut
supplementation on oxidative stress and inﬂammation markers and lipid
stratus in HD patients. Forty HD patients (57.5% men, 53.3716.1yrs) were
studied and received 1 nut (around 5g) a day for three months. The GSH-Px,
8-isoprostane, 8-OHdG, TNF-a and IL-6 levels were determined by ELISA before
and after supplementation. The LDL-c and HDL-c levels were determined by
enzymatic colorimetric method using the speciﬁc kit. After 3 months
supplementation, cytokines, 8-OHdG, 8-isoprostane levels decreased and the
activity of GSH-Px increased signiﬁcantly. Besides, after supplementation, the
HDL levels increased and LDL levels decreased signiﬁcantly.
Parameters Before supplementation After supplementation
GSH-Px (nmol/mL/min) 34.0675.2 40.378.4*
8-isoprostane (pg/mL) 12.274.5 6.674.6*
8-OHdG (pg/mL) 214.5(1.01042.0) 18.7 (1.078.8)*
IL-6 (pg/mL) 67.1 (21.180.2) 13.5 (12.822.2)*
TNF-a (pg/mL) 21.070.3 13.978.7*
HDL (mg/dL) 39.0714.2 44.77 4.8*
LDL (mg/dL) 86.0728.7 74.7729.5*
n
po .0001
The results indicate that one Brazilian nut per day is capable to improve
anti-inﬂammatory and antioxidant responses, and ameliorate lipids status
in HD patients.
http://dx.doi.org/10.1016/j.krcp.2012.04.556
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Selenium (Se) is a well-known antioxidant with a critical role in the proper
functioning of nervous and muscle functions. In the last decade, many authors
have suggested that Se may be a potent protective agent for neurons and
myocytes through selenoprotein expression in the brain, as well as in skeletal
and cardiac muscles. Low Se status has been associated with reduced
coordination, motor speed and muscle strength. Reduced muscle function is
common in hemodialysis (HD) patients; however, no study evaluated the
association betweenmuscle function and Se levels in HD patients. The objective
of this study was to correlate muscle function with Se plasma levels in HD
patients. Twenty HD patients (12 men, 54.5715.2 yr; 81.7752.8 months on
HD) from RenalCor Clinic at Rio de Janeiro, Brazil were studied. Blood samples
were collected during fasting, before a regular HD session. The Se plasma levels
were determined by atomic absorption spectrophotometry with hydride
generation (Hitachi, Z-500) and handgrip strength (HGS) was measured three
times with a mechanical dynamometer (Jamar) after HD sessions in the non-
ﬁstula side and the highest value was used for analysis. HGS values less than
the 10th percentile of an age-, gender- and regional speciﬁc reference were
considered as muscle function loss. Plasma Se levels (31.9714.8 mg/L) were
below the normal range (60-120 mg/L) and all patients were Se deﬁcient. HGS
values were signiﬁcantly greater in males (31.0711.5 kg vs 14.076.8 kg for
females) (p¼0.001) and the muscle function loss was observed in 50% of
patients and, those with muscle function loss presented low Se levels
(26.5712.1 mg/L) when compared to patients with preserved muscle function
(39.12714.5 mg/L) (p¼0.05). These data suggest that Se can have an important
role on muscle function in HD patients. However, more research is needed to
better understand this possible relationship in CKD patients.
http://dx.doi.org/10.1016/j.krcp.2012.04.557
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IS SELENIUM STATUS ASSOCIATED WITH MORTALITY RISK IN
HEMODIALYSIS PATIENTS?
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Previous studies have indicated selenium (Se) deﬁciency in hemodialysis
(HD) patients and it may increase the mortality risk for death amongnCorresponding author.
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